Neuroblastoma Drugs Market By Type (Chemotherapy, Immunotherapy, Others), By Route of Administration (Oral, Injectable), By Distribution Channel (Online, Offline): Global Opportunity Analysis and Industry Forecast, 2023-2032
The neuroblastoma drugs market was valued for $0.7 billion in 2022 and is estimated to reach $1.3 billion by 2032, exhibiting a CAGR of 6.2% from 2023 to 2032. Neuroblastoma is a type of cancer that primarily affects young children, typically arising in the adrenal glands, which are located on top of the kidneys. It is the most diagnosed disease in children under five, with most cases appearing in infants. This cancer originates from immature nerve cells, called neuroblasts, which are part of the sympathetic nervous system responsible for the fight or flight response.
Neuroblastoma varies widely in its behavior, ranging from spontaneous regression or maturation to aggressive, rapidly spreading forms. Symptoms of neuroblastoma can vary based on the location and size of the tumor but may include abdominal swelling, weight loss, irritability, fatigue, and changes in bowel habits. Neuroblastoma drugs are designed to target and inhibit the growth of cancerous neuroblastoma cells, either by directly attacking the cancer cells or by modulating the biological pathways involved in tumor development. The treatment approach for neuroblastoma often involves a combination of surgery, chemotherapy, radiation therapy, immunotherapy, and other targeted therapies.
The neuroblastoma drugs market is driven by a rise in incidences of neuroblastoma, advancements in R&D activities, and growth in awareness of neuroblastoma. The increasing incidences and prevalence of neuroblastoma, particularly among pediatric populations, is a pivotal factor driving the growth of the neuroblastoma drugs market. For instance, according to the National Center for Biotechnology and Information (NCBI) in 2023, the annual incidence of neuroblastoma in the U.S. was approximately 650 cases, i.e., 10.2 per million children. Thus, the growing prevalence of neuroblastoma led to an urgent need for effective and targeted drug therapies which contribute toward the market growth.
Consequently, pharmaceutical companies and research institutions are compelled to intensify their efforts in drug development, clinical trials, and collaborative research initiatives to address this rising health concern. The market's response to the increasing disease burden emphasizes the importance of advancing innovative treatments to improve outcomes and quality of life for individuals affected by neuroblastoma. In addition, the pharmaceutical industry has been witnessing significant investments in oncology research and drug development, thereby boosting the market growth. Neuroblastoma, as a subset of pediatric oncology, benefits from this broader trend, with increased funding and resources allocated to discovering and developing novel drugs. For instance, the National Cancer Institute (NCI) has made substantial investments in basic research, leading to the development of dinutuximab, a treatment for neuroblastoma.
However, the high cost of neuroblastoma treatment, and harmful side effects associated with neuroblastoma drugs are the factors responsible for the impeding the growth of the neuroblastoma drug market. In contrast, rise in number of pipeline drugs for neuroblastoma provides lucrative opportunity to the market growth. In addition, the exploration of combination therapies involving different classes of drugs, such as traditional chemotherapeutics, targeted agents, and immunotherapies, offers opportunities for enhanced treatment efficacy.
The neuroblastoma drugs market is segmented into type, route of administration, distribution channel, and region. By type, the market is classified into chemotherapy, immunotherapy, and others. By route of administration, the market is segregated into oral and injectable. By distribution channel, the market is classified into online and offline. Region wise, the market is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (Japan, China, India, Australia, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA). Major key players that operate in the neuroblastoma drugs market are Recordati Group,, AstraZeneca plc, Bristol-Myers Squibb Company, Cellectar Biosciences, Inc., Eli Lilly and Company, MacroGenics Inc, Pfizer, Inc., Teva Pharmaceutical Industries Ltd., United Therapeutics Corporation, and Y-mabs Therapeutics, Inc. Key players operating in the market have adopted agreement, acquisition, partnership, and product approval as their key strategies to expand their product portfolio.
Key Benefits For Stakeholders
This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the neuroblastoma drugs market analysis from 2022 to 2032 to identify the prevailing neuroblastoma drugs market opportunities.
The market research is offered along with information related to key drivers, restraints, and opportunities.
Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
In-depth analysis of the neuroblastoma drugs market segmentation assists to determine the prevailing market opportunities.
Major countries in each region are mapped according to their revenue contribution to the global market.
Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
The report includes the analysis of the regional as well as global neuroblastoma drugs market trends, key players, market segments, application areas, and market growth strategies.
Key Market Segments
By Type
Chemotherapy
Immunotherapy
Others
By Route of Administration
Oral
Injectable
By Distribution Channel
Online
Offline
By Region
North America
U.S.
Canada
Mexico
Europe
Germany
France
UK
Italy
Spain
Rest of Europe
Asia-Pacific
Japan
China
India
Australia
South Korea
Rest of Asia-Pacific
LAMEA
Brazil
Saudi Arabia
South Africa
Rest of LAMEA
Key Market Players
AstraZeneca plc
Bristol-Myers Squibb Company
Cellectar Biosciences, Inc.
Eli Lilly and Company
Pfizer Inc.
Teva Pharmaceutical Industries Ltd.
United Therapeutics Corporation
Y-mabs Therapeutics, Inc.
Recordati Group
MacroGenics Inc.
Please Note: It will take 7-10 business days to complete the report upon order confirmation.
- CHAPTER 1: INTRODUCTION
- 1.1. Report description
- 1.2. Key market segments
- 1.3. Key benefits to the stakeholders
- 1.4. Research methodology
- 1.4.1. Primary research
- 1.4.2. Secondary research
- 1.4.3. Analyst tools and models
- CHAPTER 2: EXECUTIVE SUMMARY
- 2.1. CXO Perspective
- CHAPTER 3: MARKET OVERVIEW
- 3.1. Market definition and scope
- 3.2. Key findings
- 3.2.1. Top impacting factors
- 3.2.2. Top investment pockets
- 3.3. Porter’s five forces analysis
- 3.3.1. Moderate bargaining power of suppliers
- 3.3.2. Moderate threat of new entrants
- 3.3.3. Moderate threat of substitutes
- 3.3.4. Moderate intensity of rivalry
- 3.3.5. Moderate bargaining power of buyers
- 3.4. Market dynamics
- 3.4.1. Drivers
- 3.4.1.1. Rise in prevalence of neuroblastoma
- 3.4.1.2. Growth in awareness & initiatives taken by the government for neuroblastoma
- 3.4.1.3. Rise in R&D activities
- 3.4.2. Restraints
- 3.4.2.1. Adverse effects and safety concerns
- 3.4.3. Opportunities
- 3.4.3.1. Growth opportunities in emerging markets
- 3.4.3.2. Rise in number of pipeline products
- CHAPTER 4: NEUROBLASTOMA DRUGS MARKET, BY TYPE
- 4.1. Overview
- 4.1.1. Market size and forecast
- 4.2. Chemotherapy
- 4.2.1. Key market trends, growth factors and opportunities
- 4.2.2. Market size and forecast, by region
- 4.2.3. Market share analysis by country
- 4.3. Immunotherapy
- 4.3.1. Key market trends, growth factors and opportunities
- 4.3.2. Market size and forecast, by region
- 4.3.3. Market share analysis by country
- 4.4. Others
- 4.4.1. Key market trends, growth factors and opportunities
- 4.4.2. Market size and forecast, by region
- 4.4.3. Market share analysis by country
- CHAPTER 5: NEUROBLASTOMA DRUGS MARKET, BY ROUTE OF ADMINISTRATION
- 5.1. Overview
- 5.1.1. Market size and forecast
- 5.2. Oral
- 5.2.1. Key market trends, growth factors and opportunities
- 5.2.2. Market size and forecast, by region
- 5.2.3. Market share analysis by country
- 5.3. Injectable
- 5.3.1. Key market trends, growth factors and opportunities
- 5.3.2. Market size and forecast, by region
- 5.3.3. Market share analysis by country
- CHAPTER 6: NEUROBLASTOMA DRUGS MARKET, BY DISTRIBUTION CHANNEL
- 6.1. Overview
- 6.1.1. Market size and forecast
- 6.2. Online
- 6.2.1. Key market trends, growth factors and opportunities
- 6.2.2. Market size and forecast, by region
- 6.2.3. Market share analysis by country
- 6.3. Offline
- 6.3.1. Key market trends, growth factors and opportunities
- 6.3.2. Market size and forecast, by region
- 6.3.3. Market share analysis by country
- CHAPTER 7: NEUROBLASTOMA DRUGS MARKET, BY REGION
- 7.1. Overview
- 7.1.1. Market size and forecast By Region
- 7.2. North America
- 7.2.1. Key market trends, growth factors and opportunities
- 7.2.2. Market size and forecast, by Type
- 7.2.3. Market size and forecast, by Route of Administration
- 7.2.4. Market size and forecast, by Distribution Channel
- 7.2.5. Market size and forecast, by country
- 7.2.5.1. U.S.
- 7.2.5.1.1. Market size and forecast, by Type
- 7.2.5.1.2. Market size and forecast, by Route of Administration
- 7.2.5.1.3. Market size and forecast, by Distribution Channel
- 7.2.5.2. Canada
- 7.2.5.2.1. Market size and forecast, by Type
- 7.2.5.2.2. Market size and forecast, by Route of Administration
- 7.2.5.2.3. Market size and forecast, by Distribution Channel
- 7.2.5.3. Mexico
- 7.2.5.3.1. Market size and forecast, by Type
- 7.2.5.3.2. Market size and forecast, by Route of Administration
- 7.2.5.3.3. Market size and forecast, by Distribution Channel
- 7.3. Europe
- 7.3.1. Key market trends, growth factors and opportunities
- 7.3.2. Market size and forecast, by Type
- 7.3.3. Market size and forecast, by Route of Administration
- 7.3.4. Market size and forecast, by Distribution Channel
- 7.3.5. Market size and forecast, by country
- 7.3.5.1. Germany
- 7.3.5.1.1. Market size and forecast, by Type
- 7.3.5.1.2. Market size and forecast, by Route of Administration
- 7.3.5.1.3. Market size and forecast, by Distribution Channel
- 7.3.5.2. France
- 7.3.5.2.1. Market size and forecast, by Type
- 7.3.5.2.2. Market size and forecast, by Route of Administration
- 7.3.5.2.3. Market size and forecast, by Distribution Channel
- 7.3.5.3. UK
- 7.3.5.3.1. Market size and forecast, by Type
- 7.3.5.3.2. Market size and forecast, by Route of Administration
- 7.3.5.3.3. Market size and forecast, by Distribution Channel
- 7.3.5.4. Italy
- 7.3.5.4.1. Market size and forecast, by Type
- 7.3.5.4.2. Market size and forecast, by Route of Administration
- 7.3.5.4.3. Market size and forecast, by Distribution Channel
- 7.3.5.5. Spain
- 7.3.5.5.1. Market size and forecast, by Type
- 7.3.5.5.2. Market size and forecast, by Route of Administration
- 7.3.5.5.3. Market size and forecast, by Distribution Channel
- 7.3.5.6. Rest of Europe
- 7.3.5.6.1. Market size and forecast, by Type
- 7.3.5.6.2. Market size and forecast, by Route of Administration
- 7.3.5.6.3. Market size and forecast, by Distribution Channel
- 7.4. Asia-Pacific
- 7.4.1. Key market trends, growth factors and opportunities
- 7.4.2. Market size and forecast, by Type
- 7.4.3. Market size and forecast, by Route of Administration
- 7.4.4. Market size and forecast, by Distribution Channel
- 7.4.5. Market size and forecast, by country
- 7.4.5.1. Japan
- 7.4.5.1.1. Market size and forecast, by Type
- 7.4.5.1.2. Market size and forecast, by Route of Administration
- 7.4.5.1.3. Market size and forecast, by Distribution Channel
- 7.4.5.2. China
- 7.4.5.2.1. Market size and forecast, by Type
- 7.4.5.2.2. Market size and forecast, by Route of Administration
- 7.4.5.2.3. Market size and forecast, by Distribution Channel
- 7.4.5.3. India
- 7.4.5.3.1. Market size and forecast, by Type
- 7.4.5.3.2. Market size and forecast, by Route of Administration
- 7.4.5.3.3. Market size and forecast, by Distribution Channel
- 7.4.5.4. Australia
- 7.4.5.4.1. Market size and forecast, by Type
- 7.4.5.4.2. Market size and forecast, by Route of Administration
- 7.4.5.4.3. Market size and forecast, by Distribution Channel
- 7.4.5.5. South Korea
- 7.4.5.5.1. Market size and forecast, by Type
- 7.4.5.5.2. Market size and forecast, by Route of Administration
- 7.4.5.5.3. Market size and forecast, by Distribution Channel
- 7.4.5.6. Rest of Asia-Pacific
- 7.4.5.6.1. Market size and forecast, by Type
- 7.4.5.6.2. Market size and forecast, by Route of Administration
- 7.4.5.6.3. Market size and forecast, by Distribution Channel
- 7.5. LAMEA
- 7.5.1. Key market trends, growth factors and opportunities
- 7.5.2. Market size and forecast, by Type
- 7.5.3. Market size and forecast, by Route of Administration
- 7.5.4. Market size and forecast, by Distribution Channel
- 7.5.5. Market size and forecast, by country
- 7.5.5.1. Brazil
- 7.5.5.1.1. Market size and forecast, by Type
- 7.5.5.1.2. Market size and forecast, by Route of Administration
- 7.5.5.1.3. Market size and forecast, by Distribution Channel
- 7.5.5.2. Saudi Arabia
- 7.5.5.2.1. Market size and forecast, by Type
- 7.5.5.2.2. Market size and forecast, by Route of Administration
- 7.5.5.2.3. Market size and forecast, by Distribution Channel
- 7.5.5.3. South Africa
- 7.5.5.3.1. Market size and forecast, by Type
- 7.5.5.3.2. Market size and forecast, by Route of Administration
- 7.5.5.3.3. Market size and forecast, by Distribution Channel
- 7.5.5.4. Rest of LAMEA
- 7.5.5.4.1. Market size and forecast, by Type
- 7.5.5.4.2. Market size and forecast, by Route of Administration
- 7.5.5.4.3. Market size and forecast, by Distribution Channel
- CHAPTER 8: COMPETITIVE LANDSCAPE
- 8.1. Introduction
- 8.2. Top winning strategies
- 8.3. Product mapping of top 10 player
- 8.4. Competitive dashboard
- 8.5. Competitive heatmap
- 8.6. Top player positioning, 2022
- CHAPTER 9: COMPANY PROFILES
- 9.1. Recordati Group
- 9.1.1. Company overview
- 9.1.2. Key executives
- 9.1.3. Company snapshot
- 9.1.4. Operating business segments
- 9.1.5. Product portfolio
- 9.1.6. Business performance
- 9.1.7. Key strategic moves and developments
- 9.2. AstraZeneca plc
- 9.2.1. Company overview
- 9.2.2. Key executives
- 9.2.3. Company snapshot
- 9.2.4. Operating business segments
- 9.2.5. Product portfolio
- 9.2.6. Business performance
- 9.3. Bristol-Myers Squibb Company
- 9.3.1. Company overview
- 9.3.2. Key executives
- 9.3.3. Company snapshot
- 9.3.4. Operating business segments
- 9.3.5. Product portfolio
- 9.3.6. Business performance
- 9.4. Cellectar Biosciences, Inc.
- 9.4.1. Company overview
- 9.4.2. Key executives
- 9.4.3. Company snapshot
- 9.4.4. Operating business segments
- 9.4.5. Product portfolio
- 9.5. Eli Lilly and Company
- 9.5.1. Company overview
- 9.5.2. Key executives
- 9.5.3. Company snapshot
- 9.5.4. Operating business segments
- 9.5.5. Product portfolio
- 9.5.6. Business performance
- 9.6. MacroGenics Inc.
- 9.6.1. Company overview
- 9.6.2. Key executives
- 9.6.3. Company snapshot
- 9.6.4. Operating business segments
- 9.6.5. Product portfolio
- 9.6.6. Business performance
- 9.7. Pfizer Inc.
- 9.7.1. Company overview
- 9.7.2. Key executives
- 9.7.3. Company snapshot
- 9.7.4. Operating business segments
- 9.7.5. Product portfolio
- 9.7.6. Business performance
- 9.8. Teva Pharmaceutical Industries Ltd.
- 9.8.1. Company overview
- 9.8.2. Key executives
- 9.8.3. Company snapshot
- 9.8.4. Operating business segments
- 9.8.5. Product portfolio
- 9.8.6. Business performance
- 9.9. United Therapeutics Corporation
- 9.9.1. Company overview
- 9.9.2. Key executives
- 9.9.3. Company snapshot
- 9.9.4. Operating business segments
- 9.9.5. Product portfolio
- 9.9.6. Business performance
- 9.9.7. Key strategic moves and developments
- 9.10. Y-mabs Therapeutics, Inc.
- 9.10.1. Company overview
- 9.10.2. Key executives
- 9.10.3. Company snapshot
- 9.10.4. Operating business segments
- 9.10.5. Product portfolio
- 9.10.6. Business performance
- 9.10.7. Key strategic moves and developments
- LIST OF TABLES
- TABLE 01. GLOBAL NEUROBLASTOMA DRUGS MARKET, BY TYPE, 2022-2032 ($MILLION)
- TABLE 02. NEUROBLASTOMA DRUGS MARKET FOR CHEMOTHERAPY, BY REGION, 2022-2032 ($MILLION)
- TABLE 03. NEUROBLASTOMA DRUGS MARKET FOR IMMUNOTHERAPY, BY REGION, 2022-2032 ($MILLION)
- TABLE 04. NEUROBLASTOMA DRUGS MARKET FOR OTHERS, BY REGION, 2022-2032 ($MILLION)
- TABLE 05. GLOBAL NEUROBLASTOMA DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
- TABLE 06. NEUROBLASTOMA DRUGS MARKET FOR ORAL, BY REGION, 2022-2032 ($MILLION)
- TABLE 07. NEUROBLASTOMA DRUGS MARKET FOR INJECTABLE, BY REGION, 2022-2032 ($MILLION)
- TABLE 08. GLOBAL NEUROBLASTOMA DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
- TABLE 09. NEUROBLASTOMA DRUGS MARKET FOR ONLINE, BY REGION, 2022-2032 ($MILLION)
- TABLE 10. NEUROBLASTOMA DRUGS MARKET FOR OFFLINE, BY REGION, 2022-2032 ($MILLION)
- TABLE 11. NEUROBLASTOMA DRUGS MARKET, BY REGION, 2022-2032 ($MILLION)
- TABLE 12. NORTH AMERICA NEUROBLASTOMA DRUGS MARKET, BY TYPE, 2022-2032 ($MILLION)
- TABLE 13. NORTH AMERICA NEUROBLASTOMA DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
- TABLE 14. NORTH AMERICA NEUROBLASTOMA DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
- TABLE 15. NORTH AMERICA NEUROBLASTOMA DRUGS MARKET, BY COUNTRY, 2022-2032 ($MILLION)
- TABLE 16. U.S. NEUROBLASTOMA DRUGS MARKET, BY TYPE, 2022-2032 ($MILLION)
- TABLE 17. U.S. NEUROBLASTOMA DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
- TABLE 18. U.S. NEUROBLASTOMA DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
- TABLE 19. CANADA NEUROBLASTOMA DRUGS MARKET, BY TYPE, 2022-2032 ($MILLION)
- TABLE 20. CANADA NEUROBLASTOMA DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
- TABLE 21. CANADA NEUROBLASTOMA DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
- TABLE 22. MEXICO NEUROBLASTOMA DRUGS MARKET, BY TYPE, 2022-2032 ($MILLION)
- TABLE 23. MEXICO NEUROBLASTOMA DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
- TABLE 24. MEXICO NEUROBLASTOMA DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
- TABLE 25. EUROPE NEUROBLASTOMA DRUGS MARKET, BY TYPE, 2022-2032 ($MILLION)
- TABLE 26. EUROPE NEUROBLASTOMA DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
- TABLE 27. EUROPE NEUROBLASTOMA DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
- TABLE 28. EUROPE NEUROBLASTOMA DRUGS MARKET, BY COUNTRY, 2022-2032 ($MILLION)
- TABLE 29. GERMANY NEUROBLASTOMA DRUGS MARKET, BY TYPE, 2022-2032 ($MILLION)
- TABLE 30. GERMANY NEUROBLASTOMA DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
- TABLE 31. GERMANY NEUROBLASTOMA DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
- TABLE 32. FRANCE NEUROBLASTOMA DRUGS MARKET, BY TYPE, 2022-2032 ($MILLION)
- TABLE 33. FRANCE NEUROBLASTOMA DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
- TABLE 34. FRANCE NEUROBLASTOMA DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
- TABLE 35. UK NEUROBLASTOMA DRUGS MARKET, BY TYPE, 2022-2032 ($MILLION)
- TABLE 36. UK NEUROBLASTOMA DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
- TABLE 37. UK NEUROBLASTOMA DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
- TABLE 38. ITALY NEUROBLASTOMA DRUGS MARKET, BY TYPE, 2022-2032 ($MILLION)
- TABLE 39. ITALY NEUROBLASTOMA DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
- TABLE 40. ITALY NEUROBLASTOMA DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
- TABLE 41. SPAIN NEUROBLASTOMA DRUGS MARKET, BY TYPE, 2022-2032 ($MILLION)
- TABLE 42. SPAIN NEUROBLASTOMA DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
- TABLE 43. SPAIN NEUROBLASTOMA DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
- TABLE 44. REST OF EUROPE NEUROBLASTOMA DRUGS MARKET, BY TYPE, 2022-2032 ($MILLION)
- TABLE 45. REST OF EUROPE NEUROBLASTOMA DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
- TABLE 46. REST OF EUROPE NEUROBLASTOMA DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
- TABLE 47. ASIA-PACIFIC NEUROBLASTOMA DRUGS MARKET, BY TYPE, 2022-2032 ($MILLION)
- TABLE 48. ASIA-PACIFIC NEUROBLASTOMA DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
- TABLE 49. ASIA-PACIFIC NEUROBLASTOMA DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
- TABLE 50. ASIA-PACIFIC NEUROBLASTOMA DRUGS MARKET, BY COUNTRY, 2022-2032 ($MILLION)
- TABLE 51. JAPAN NEUROBLASTOMA DRUGS MARKET, BY TYPE, 2022-2032 ($MILLION)
- TABLE 52. JAPAN NEUROBLASTOMA DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
- TABLE 53. JAPAN NEUROBLASTOMA DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
- TABLE 54. CHINA NEUROBLASTOMA DRUGS MARKET, BY TYPE, 2022-2032 ($MILLION)
- TABLE 55. CHINA NEUROBLASTOMA DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
- TABLE 56. CHINA NEUROBLASTOMA DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
- TABLE 57. INDIA NEUROBLASTOMA DRUGS MARKET, BY TYPE, 2022-2032 ($MILLION)
- TABLE 58. INDIA NEUROBLASTOMA DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
- TABLE 59. INDIA NEUROBLASTOMA DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
- TABLE 60. AUSTRALIA NEUROBLASTOMA DRUGS MARKET, BY TYPE, 2022-2032 ($MILLION)
- TABLE 61. AUSTRALIA NEUROBLASTOMA DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
- TABLE 62. AUSTRALIA NEUROBLASTOMA DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
- TABLE 63. SOUTH KOREA NEUROBLASTOMA DRUGS MARKET, BY TYPE, 2022-2032 ($MILLION)
- TABLE 64. SOUTH KOREA NEUROBLASTOMA DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
- TABLE 65. SOUTH KOREA NEUROBLASTOMA DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
- TABLE 66. REST OF ASIA-PACIFIC NEUROBLASTOMA DRUGS MARKET, BY TYPE, 2022-2032 ($MILLION)
- TABLE 67. REST OF ASIA-PACIFIC NEUROBLASTOMA DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
- TABLE 68. REST OF ASIA-PACIFIC NEUROBLASTOMA DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
- TABLE 69. LAMEA NEUROBLASTOMA DRUGS MARKET, BY TYPE, 2022-2032 ($MILLION)
- TABLE 70. LAMEA NEUROBLASTOMA DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
- TABLE 71. LAMEA NEUROBLASTOMA DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
- TABLE 72. LAMEA NEUROBLASTOMA DRUGS MARKET, BY COUNTRY, 2022-2032 ($MILLION)
- TABLE 73. BRAZIL NEUROBLASTOMA DRUGS MARKET, BY TYPE, 2022-2032 ($MILLION)
- TABLE 74. BRAZIL NEUROBLASTOMA DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
- TABLE 75. BRAZIL NEUROBLASTOMA DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
- TABLE 76. SAUDI ARABIA NEUROBLASTOMA DRUGS MARKET, BY TYPE, 2022-2032 ($MILLION)
- TABLE 77. SAUDI ARABIA NEUROBLASTOMA DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
- TABLE 78. SAUDI ARABIA NEUROBLASTOMA DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
- TABLE 79. SOUTH AFRICA NEUROBLASTOMA DRUGS MARKET, BY TYPE, 2022-2032 ($MILLION)
- TABLE 80. SOUTH AFRICA NEUROBLASTOMA DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
- TABLE 81. SOUTH AFRICA NEUROBLASTOMA DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
- TABLE 82. REST OF LAMEA NEUROBLASTOMA DRUGS MARKET, BY TYPE, 2022-2032 ($MILLION)
- TABLE 83. REST OF LAMEA NEUROBLASTOMA DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
- TABLE 84. REST OF LAMEA NEUROBLASTOMA DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
- TABLE 85. RECORDATI GROUP: KEY EXECUTIVES
- TABLE 86. RECORDATI GROUP: COMPANY SNAPSHOT
- TABLE 87. RECORDATI GROUP: PRODUCT SEGMENTS
- TABLE 88. RECORDATI GROUP: PRODUCT PORTFOLIO
- TABLE 89. RECORDATI GROUP: KEY STRATERGIES
- TABLE 90. ASTRAZENECA PLC: KEY EXECUTIVES
- TABLE 91. ASTRAZENECA PLC: COMPANY SNAPSHOT
- TABLE 92. ASTRAZENECA PLC: PRODUCT SEGMENTS
- TABLE 93. ASTRAZENECA PLC: PRODUCT PORTFOLIO
- TABLE 94. BRISTOL-MYERS SQUIBB COMPANY: KEY EXECUTIVES
- TABLE 95. BRISTOL-MYERS SQUIBB COMPANY: COMPANY SNAPSHOT
- TABLE 96. BRISTOL-MYERS SQUIBB COMPANY: PRODUCT SEGMENTS
- TABLE 97. BRISTOL-MYERS SQUIBB COMPANY: PRODUCT PORTFOLIO
- TABLE 98. CELLECTAR BIOSCIENCES, INC.: KEY EXECUTIVES
- TABLE 99. CELLECTAR BIOSCIENCES, INC.: COMPANY SNAPSHOT
- TABLE 100. CELLECTAR BIOSCIENCES, INC.: PRODUCT SEGMENTS
- TABLE 101. CELLECTAR BIOSCIENCES, INC.: PRODUCT PORTFOLIO
- TABLE 102. ELI LILLY AND COMPANY: KEY EXECUTIVES
- TABLE 103. ELI LILLY AND COMPANY: COMPANY SNAPSHOT
- TABLE 104. ELI LILLY AND COMPANY: PRODUCT SEGMENTS
- TABLE 105. ELI LILLY AND COMPANY: PRODUCT PORTFOLIO
- TABLE 106. MACROGENICS INC.: KEY EXECUTIVES
- TABLE 107. MACROGENICS INC.: COMPANY SNAPSHOT
- TABLE 108. MACROGENICS INC.: PRODUCT SEGMENTS
- TABLE 109. MACROGENICS INC.: PRODUCT PORTFOLIO
- TABLE 110. PFIZER INC.: KEY EXECUTIVES
- TABLE 111. PFIZER INC.: COMPANY SNAPSHOT
- TABLE 112. PFIZER INC.: PRODUCT SEGMENTS
- TABLE 113. PFIZER INC.: PRODUCT PORTFOLIO
- TABLE 114. TEVA PHARMACEUTICAL INDUSTRIES LTD.: KEY EXECUTIVES
- TABLE 115. TEVA PHARMACEUTICAL INDUSTRIES LTD.: COMPANY SNAPSHOT
- TABLE 116. TEVA PHARMACEUTICAL INDUSTRIES LTD.: PRODUCT SEGMENTS
- TABLE 117. TEVA PHARMACEUTICAL INDUSTRIES LTD.: PRODUCT PORTFOLIO
- TABLE 118. UNITED THERAPEUTICS CORPORATION: KEY EXECUTIVES
- TABLE 119. UNITED THERAPEUTICS CORPORATION: COMPANY SNAPSHOT
- TABLE 120. UNITED THERAPEUTICS CORPORATION: PRODUCT SEGMENTS
- TABLE 121. UNITED THERAPEUTICS CORPORATION: PRODUCT PORTFOLIO
- TABLE 122. UNITED THERAPEUTICS CORPORATION: KEY STRATERGIES
- TABLE 123. Y-MABS THERAPEUTICS, INC.: KEY EXECUTIVES
- TABLE 124. Y-MABS THERAPEUTICS, INC.: COMPANY SNAPSHOT
- TABLE 125. Y-MABS THERAPEUTICS, INC.: PRODUCT SEGMENTS
- TABLE 126. Y-MABS THERAPEUTICS, INC.: PRODUCT PORTFOLIO
- TABLE 127. Y-MABS THERAPEUTICS, INC.: KEY STRATERGIES
- LIST OF FIGURES
- FIGURE 01. NEUROBLASTOMA DRUGS MARKET, 2022-2032
- FIGURE 02. SEGMENTATION OF NEUROBLASTOMA DRUGS MARKET,2022-2032
- FIGURE 03. TOP IMPACTING FACTORS IN NEUROBLASTOMA DRUGS MARKET (2022 TO 2032)
- FIGURE 04. TOP INVESTMENT POCKETS IN NEUROBLASTOMA DRUGS MARKET (2023-2032)
- FIGURE 05. MODERATE BARGAINING POWER OF SUPPLIERS
- FIGURE 06. MODERATE THREAT OF NEW ENTRANTS
- FIGURE 07. MODERATE THREAT OF SUBSTITUTES
- FIGURE 08. MODERATE INTENSITY OF RIVALRY
- FIGURE 09. MODERATE BARGAINING POWER OF BUYERS
- FIGURE 10. GLOBAL NEUROBLASTOMA DRUGS MARKET:DRIVERS, RESTRAINTS AND OPPORTUNITIES
- FIGURE 11. NEUROBLASTOMA DRUGS MARKET, BY TYPE, 2022 AND 2032(%)
- FIGURE 12. COMPARATIVE SHARE ANALYSIS OF NEUROBLASTOMA DRUGS MARKET FOR CHEMOTHERAPY, BY COUNTRY 2022 AND 2032(%)
- FIGURE 13. COMPARATIVE SHARE ANALYSIS OF NEUROBLASTOMA DRUGS MARKET FOR IMMUNOTHERAPY, BY COUNTRY 2022 AND 2032(%)
- FIGURE 14. COMPARATIVE SHARE ANALYSIS OF NEUROBLASTOMA DRUGS MARKET FOR OTHERS, BY COUNTRY 2022 AND 2032(%)
- FIGURE 15. NEUROBLASTOMA DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022 AND 2032(%)
- FIGURE 16. COMPARATIVE SHARE ANALYSIS OF NEUROBLASTOMA DRUGS MARKET FOR ORAL, BY COUNTRY 2022 AND 2032(%)
- FIGURE 17. COMPARATIVE SHARE ANALYSIS OF NEUROBLASTOMA DRUGS MARKET FOR INJECTABLE, BY COUNTRY 2022 AND 2032(%)
- FIGURE 18. NEUROBLASTOMA DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022 AND 2032(%)
- FIGURE 19. COMPARATIVE SHARE ANALYSIS OF NEUROBLASTOMA DRUGS MARKET FOR ONLINE, BY COUNTRY 2022 AND 2032(%)
- FIGURE 20. COMPARATIVE SHARE ANALYSIS OF NEUROBLASTOMA DRUGS MARKET FOR OFFLINE, BY COUNTRY 2022 AND 2032(%)
- FIGURE 21. NEUROBLASTOMA DRUGS MARKET BY REGION, 2022 AND 2032(%)
- FIGURE 22. U.S. NEUROBLASTOMA DRUGS MARKET, 2022-2032 ($MILLION)
- FIGURE 23. CANADA NEUROBLASTOMA DRUGS MARKET, 2022-2032 ($MILLION)
- FIGURE 24. MEXICO NEUROBLASTOMA DRUGS MARKET, 2022-2032 ($MILLION)
- FIGURE 25. GERMANY NEUROBLASTOMA DRUGS MARKET, 2022-2032 ($MILLION)
- FIGURE 26. FRANCE NEUROBLASTOMA DRUGS MARKET, 2022-2032 ($MILLION)
- FIGURE 27. UK NEUROBLASTOMA DRUGS MARKET, 2022-2032 ($MILLION)
- FIGURE 28. ITALY NEUROBLASTOMA DRUGS MARKET, 2022-2032 ($MILLION)
- FIGURE 29. SPAIN NEUROBLASTOMA DRUGS MARKET, 2022-2032 ($MILLION)
- FIGURE 30. REST OF EUROPE NEUROBLASTOMA DRUGS MARKET, 2022-2032 ($MILLION)
- FIGURE 31. JAPAN NEUROBLASTOMA DRUGS MARKET, 2022-2032 ($MILLION)
- FIGURE 32. CHINA NEUROBLASTOMA DRUGS MARKET, 2022-2032 ($MILLION)
- FIGURE 33. INDIA NEUROBLASTOMA DRUGS MARKET, 2022-2032 ($MILLION)
- FIGURE 34. AUSTRALIA NEUROBLASTOMA DRUGS MARKET, 2022-2032 ($MILLION)
- FIGURE 35. SOUTH KOREA NEUROBLASTOMA DRUGS MARKET, 2022-2032 ($MILLION)
- FIGURE 36. REST OF ASIA-PACIFIC NEUROBLASTOMA DRUGS MARKET, 2022-2032 ($MILLION)
- FIGURE 37. BRAZIL NEUROBLASTOMA DRUGS MARKET, 2022-2032 ($MILLION)
- FIGURE 38. SAUDI ARABIA NEUROBLASTOMA DRUGS MARKET, 2022-2032 ($MILLION)
- FIGURE 39. SOUTH AFRICA NEUROBLASTOMA DRUGS MARKET, 2022-2032 ($MILLION)
- FIGURE 40. REST OF LAMEA NEUROBLASTOMA DRUGS MARKET, 2022-2032 ($MILLION)
- FIGURE 41. TOP WINNING STRATEGIES, BY YEAR (2020-2023)
- FIGURE 42. TOP WINNING STRATEGIES, BY DEVELOPMENT (2020-2023)
- FIGURE 43. TOP WINNING STRATEGIES, BY COMPANY (2020-2023)
- FIGURE 44. PRODUCT MAPPING OF TOP 10 PLAYERS
- FIGURE 45. COMPETITIVE DASHBOARD
- FIGURE 46. COMPETITIVE HEATMAP: NEUROBLASTOMA DRUGS MARKET
- FIGURE 47. TOP PLAYER POSITIONING, 2022
- FIGURE 48. RECORDATI GROUP: NET REVENUE, 2020-2022 ($MILLION)
- FIGURE 49. RECORDATI GROUP: REVENUE SHARE BY SEGMENT, 2022 (%)
- FIGURE 50. RECORDATI GROUP: REVENUE SHARE BY REGION, 2022 (%)
- FIGURE 51. ASTRAZENECA PLC: NET REVENUE, 2020-2022 ($MILLION)
- FIGURE 52. ASTRAZENECA PLC: REVENUE SHARE BY REGION, 2022 (%)
- FIGURE 53. BRISTOL-MYERS SQUIBB COMPANY: NET REVENUE, 2020-2022 ($MILLION)
- FIGURE 54. BRISTOL-MYERS SQUIBB COMPANY: REVENUE SHARE BY REGION, 2022 (%)
- FIGURE 55. ELI LILLY AND COMPANY: NET REVENUE, 2020-2022 ($MILLION)
- FIGURE 56. ELI LILLY AND COMPANY: REVENUE SHARE BY REGION, 2022 (%)
- FIGURE 57. MACROGENICS INC.: NET REVENUE, 2020-2022 ($MILLION)
- FIGURE 58. PFIZER INC.: NET REVENUE, 2020-2022 ($MILLION)
- FIGURE 59. PFIZER INC.: REVENUE SHARE BY SEGMENT, 2022 (%)
- FIGURE 60. PFIZER INC.: REVENUE SHARE BY REGION, 2022 (%)
- FIGURE 61. TEVA PHARMACEUTICAL INDUSTRIES LTD.: NET REVENUE, 2020-2022 ($MILLION)
- FIGURE 62. TEVA PHARMACEUTICAL INDUSTRIES LTD.: REVENUE SHARE BY SEGMENT, 2022 (%)
- FIGURE 63. TEVA PHARMACEUTICAL INDUSTRIES LTD.: REVENUE SHARE BY REGION, 2022 (%)
- FIGURE 64. UNITED THERAPEUTICS CORPORATION: NET SALES, 2020-2022 ($MILLION)
- FIGURE 65. UNITED THERAPEUTICS CORPORATION: REVENUE SHARE BY REGION, 2022 (%)
- FIGURE 66. Y-MABS THERAPEUTICS, INC.: NET REVENUE, 2020-2022 ($MILLION)
Research Assistance
Download our eBook: How to Succeed Using Market Research
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook